Australia faces immediate disruption to treatment pathways for people who rely on the monthly Zoladex implant as the drug is removed from the Pharmaceutical Benefits Scheme effective 1 November 2026. AstraZeneca and patient groups say a company run Continuity Program will provide access to the 3.6 milligram monthly implant for eligible patients, but clinicians and advocacy organisations warn that the change transfers long term access decisions from a public subsidy framework to arrangements controlled by a private company.

What is changing on November 1

The removal affects the 3.6 milligram monthly Zoladex implant, a gonadotropin releasing hormone agonist widely used to manage endometriosis symptoms and used in some breast cancer contexts. From 1 November the product will no longer be listed on the PBS. AstraZeneca has established a Zoladex Continuity Program so that people who are already prescribed the monthly implant, and new patients for whom clinicians judge it clinically necessary, can continue to receive the medicine without immediate out of pocket cost under the company program.

AstraZeneca told health sector stakeholders earlier this year that the Continuity Program would be activated at the time the product left the PBS, and that it intended to keep supplying eligible patients while longer term arrangements were clarified. Patient advocacy groups say the program registration window opened before November to avoid sudden interruptions to treatment.

How many people could be affected

Estimates from patient groups and prescribing data suggest tens of thousands of Zoladex prescriptions are written annually in Australia for a mixture of indications. Breast Cancer Network Australia and endometriosis advocacy groups have previously highlighted that several thousand women each year depend on the monthly implant for symptom control or as part of oncological care. The precise number of patients who will rely on the Continuity Program is not publicly disclosed by the company and will depend on clinicians enrolling patients and on supply capacity.

Doctors and advocates warn of uneven access and unanswered questions

Clinicians and patient organisations welcomed that a no cost route has been put in place for many patients, but they expressed concern about the loss of the PBS safety net and the uncertainty about the program’s duration and eligibility criteria. Under the PBS, eligible patients benefit from standardised criteria, predictable supply chains and safety nets for heavy users. A company administered program may change terms with limited public oversight.

Patient groups have also flagged that some people could face delays or administrative barriers to enrolling in the continuity scheme, and that alternative formulations used for other indications are not a simple substitute for the monthly implant for all patients. In addition, a three month, higher dose implant is licensed for prostate cancer in Australia but is not broadly approved or clinically trialled for endometriosis, limiting substitution options for many women.

Government response and regulator steps

Regulatory bodies including the Therapeutic Goods Administration and the Department of Health have been monitoring supply arrangements. The TGA maintains a public medicines shortages and substitution advisory framework and has previously issued temporary approvals to import overseas registered alternatives when Australian supply risks arise. Officials say they are in contact with the sponsor and with specialist clinical groups to manage transition risks.

Health policy experts say the episode highlights how market decisions by global pharmaceutical companies can produce sudden changes in publicly funded medicine lists. The Pharmaceutical Benefits Scheme manages public subsidy for a large number of essential medicines and changes to listings typically follow review processes. When a sponsor elects to withdraw a product for commercial reasons, the options are limited: negotiate a new listing arrangement, arrange a company continuity supply, or rely on the TGA and other sponsors to allow alternative products to fill the gap.

What patients should do now

Specialist clinicians and patient groups advise patients currently taking the monthly Zoladex implant to contact their treating specialist or GP without delay to confirm enrolment in any continuity arrangements and to discuss clinical alternatives where appropriate. Patients newly requiring treatment should also consult their prescriber to establish whether they are eligible for the program and to ensure there is no interruption to care.

Advocacy organisations have set up information pages and hotlines to help people navigate the transition. They are also pressing for clear, publicly available information on how long the Continuity Program will operate, what clinical criteria apply for new patients, and for assurances that supply will be stable while alternatives are considered.

Why this matters

The removal of a widely used endocrine therapy from the PBS and its replacement with a company continuity program underscores growing fragility in the medicines access landscape. For patients with chronic, painful conditions such as endometriosis and for some people with hormone sensitive breast cancers, predictable access to a specific formulation can be clinically important. When that access is shifted from a government subsidy scheme to an ad hoc commercial program, the health system and patients become dependent on private supply decisions.

Clinicians and patient advocates say they will be watching for any signs of supply disruption and for government action to secure longer term solutions. In the short term, the Continuity Program should reduce immediate harm, but it leaves open questions about affordability, oversight and the future availability of the monthly Zoladex implant beyond the period a company chooses to provide it free to eligible patients.

Patients and clinicians seeking the most recent guidance are advised to consult their treating teams and the Therapeutic Goods Administration medicines shortage notices for updates.